Yet another CSF1R trial combotherapy is opening up with PDL1. This is the 3rd or 4th trial to focuss this combo on MSS-CRC. So far it looks like a French/ European trial (so far!) for our European members or perhaps some us have French connections. The fact that 3-4 companies are independently trying this strategy on MSS-CRC, implies that they each have found activity in pre-clinical models. Here is the NCT# NCT02777710 and the link https://clinicaltrials.gov/ct2/show/NCT ... 16&rank=32
The anti-CSF1R is meant to remove immunosuppressive macrophages from the tumor.
-DK37'